Vibration-controlled transient elastography estimates liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), which are noninvasive assessments of hepatic fibrosis and steatosis, respectively. However, prior vibrationcontrolled transient elastography studies reported high failure rates in patients with nonalcoholic fatty liver disease. We examined the performance characteristics of the FibroScan 502 Touch with two probes, medium (M1) and extra large (XL1), in patients with nonalcoholic fatty liver disease in a multicenter setting. A total of 1,696 exams were attempted in 992 patients (body mass index, 33.6 6 6.5 kg/m 2 ) with histologically confirmed nonalcoholic fatty liver disease. Simultaneous assessment of LSM and CAP was performed using the FibroScan 502 Touch with an automatic probe selection tool. Testing was conducted twice in patients by either a single operator (87%) or two operators (13%). Failure was defined as the inability to obtain a valid examination. An examination was considered unreliable if LSM interquartile range/ median was >30%. Significant disagreement between two readings was defined as >95% limits of agreement between two readings. A total of 1,641 examinations yielded valid results with a failure rate of 3.2% (55/1,696). The proportion of unreliable scans for LSM was 3.9%. The proportion of unreliable scans with operator experience in the top quartile (59 procedures) was significantly lower than that in the lower three quarters combined (1.6% versus 4.7%, P 5 0.02 by Fisher's exact test). The significant disagreement between first and second readings for LSM and CAP when obtained back to back was 18% and 11%, respectively. Conclusion: Vibration-controlled transient elastography for estimation of LSM and CAP can be successfully deployed in a multicenter setting with low failure (3.2%) and high reliability (>95%) rates and high reproducibility. (HEPATOLOGY 2018;67:134-144).
N onalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease and is estimated to occur in up to one third of individuals in the United States. (1) The clinical spectrum of NAFLD ranges from relatively benign nonalcoholic fatty liver to nonalcoholic steatohepatitis (NASH) that can progress to cirrhosis, liver failure, or hepatocellular cancer. (2, 3) In nonalcoholic fatty liver only macrosteatosis is present on liver biopsy, whereas in NASH macrosteatosis is present with a variable mix of hepatocyte ballooning and inflammation with or without fibrosis. (4, 5) The distinction of different forms of NAFLD is important in the clinical management due to very different prognoses. (6, 7) Furthermore, fibrosis has emerged as the strongest predictor of long-term outcomes in patients with NAFLD. (8) Liver biopsy has long been regarded as the gold standard for diagnosis and prognostication of patients with NAFLD. (9) However, histological interpretation of liver biopsy is subject to micro-inhomogeneity of liver tissue, sampling error based on length of liver biopsy core, presence of unfragmented core, and observer variability among pathologists. (10, 11) Moreover, it requires the patient to undergo an invasive procedure that could be associated with discomfort and could rarely be associated with life-threatening complications. (12) (13) (14) Liver stiffness measurement (LSM) assessed by vibration-controlled transient elastography (VCTE) has been shown to be an easy-to-perform, noninvasive test to reliably estimate the degree of liver fibrosis in patients with NAFLD. (15) (16) (17) (18) (19) VCTE measures the speed of a mechanically induced shear wave using pulse-echo ultrasonic acquisitions in a much larger portion of the tissue, approximately 100 times more than a liver biopsy core. However, prior studies evaluating the performance of VCTE in NAFLD have been limited by medium (M1) size probes with an ultrasound probe frequency of 3.5 MHz to measure LSM at a depth of 2.5 and 6.5 cm from the skin. (20, 21) However, using the M1 probe alone, the LSM was not reliable in a substantial number of patients, with body mass index (BMI) as the major determinant for diagnostic errors in predicting fibrosis by either overestimating or underestimating the stage of fibrosis. (22, 23) The failure rates reported in these studies have been as high as 25%, presumably due to skin to liver capsule distance >2.5 cm. (20, 21, 24) Despite the failure rates, several studies have reported correlation between stage of liver fibrosis and LSM values in patients with NAFLD. (20, (25) (26) (27) The optimal cutoff values corresponding to various stages of fibrosis, however, have not been very apparent due to overlapping values of LSM across various stages. A recent study from the NASH Clinical Research Network (NASH CRN) reported that LSM of 15.5 kPa had an area under the receiver operating characteristic curve of 0.93 for differentiating cirrhosis from noncirrhosis stage of fibrosis with a specificity of 90%. (28) The newer version of VCTE, available in the United States since early 2013, has several features that not only overcome its prior limitations but also enhance its role as a diagnostic tool in the evaluation of patients with NAFLD. First, it is approved by the regulatory authorities to measure a 3.5-MHz ultrasound coefficient of attenuation (controlled attenuation parameter [CAP] , the ultrasonic attenuation in the liver tissue depends on the viscosity [fat] of the medium [liver] and the distance of propagation of the ultrasonic signals into the liver). (29, 30) While LSM is measured in kilopascals, CAP is measured in decibels per meter and reflects the decrease in the amplitude of ultrasound signal in the liver. (30) (31) (32) Therefore, a higher CAP is reflective of the higher degree of steatosis. CAP is displayed only when LSM is valid as it is only computed from the ultrasound signals used for acquiring LSM. The shear wave speed with estimation of stiffness and CAP currently allow for simultaneous assessment of both liver fibrosis and steatosis. (33, 34) Several studies have also reported a good correlation between degree of hepatic steatosis or hepatic fat content by magnetic resonance imaging-proton density fat fraction. (35, 36) Second is the availability of an extra large (XL1) probe with an ultrasound frequency of 2.5 MHz for measurement of shear wave at skin to liver capsule depths of 3.5 and 7.5 cm. Lastly is the availability of an automatic probe selection software tool that determines the choice of the probe based on the skin liver capsule distance. It is therefore possible that the failure rate of current VCTE may be much lower than that of the previous version in the evaluation of NAFLD. (23, 30, 37) The aim of the current study was to report the success and reliability of the newer FibroScan 502 Touch, which offers a machine-derived choice between the M1 and XL1 probes for simultaneous assessment of LSM and CAP in patients with NAFLD, particularly in a multicenter setting. Furthermore, a thorough understanding of factors that could potentially influence the LSM and CAP values is necessary.
Participants and Methods

STUDY DESIGN
Individuals who are 18 years with histologically proven NAFLD and participating in the prospective NAFLD Database 2 study underwent simultaneous assessment for LSM and CAP using the FibroScan 502 Touch (Echosens North America, Waltham, MA). The NAFLD Database 2 study was initiated by the NASH CRN in December 2009, and its inclusion and exclusion criteria are similar to the previously reported NASH CRN Database study except that all participants required histologically confirmed NAFLD for eligibility. (38) (38) This study (NCT01030484) was approved by the institutional review boards of the respective participating institutions, and all participants provided written informed consent prior to enrollment. No employees of Echosens were investigators in this study or controlled the acquisition, analysis, interpretation, or reporting of results.
STUDY VISIT AND PROCEDURES
All participants presented for an outpatient study visit after 12 hours of fasting to the respective clinical research center after an overnight fast and were evaluated by the study nurse and the clinical investigator. Participants underwent anthropometric measurements and completed study-specific questionnaires, physical examination, and blood tests. Routine laboratory studies were performed on fresh samples in Clinical Laboratory Improvement Amendments-certified laboratories at each clinical site according to standard clinical protocols. (38) 
EQUIPMENT AND TECHNICIAN EXPERTISE
The FibroScan 502 Touch with two probes, M1 and XL1, was available at each of the participating medical centers for measuring LSM and CAP. The type of probe required for each participant was based on the automatic probe selection tool embedded within the FibroScan 502 Touch operating software. These machines were provided by the Echosens company to adult clinical centers of the NASH CRN through a clinical trials agreement between Echosens and the National Institute of Diabetes and Digestive and Kidney Diseases.
All studies were performed by a dedicated study coordinator at each site using a standardized protocol. (38) All study coordinators were new to the FibroScan technology and underwent standardized training (didactic followed by hands-on testing in 5 participants under the supervision of a proctor) by Echosens and were certified before conducting VCTEs for the current study.
Each patient was placed supine with the right arm raised behind his or her head and remained still during the procedure. With the probe over the liver region, readings were attempted until 10 valid measurements were obtained. All studies were started with an M1 probe, with the XL1 probe as rescue only when prompted by the automatic probe selection tool. In rare instances, where the machine's recommendation fluctuated between the M1 and XL1 probes, the study coordinator was instructed to choose the XL1 probe. Two scans were performed during the same visit several minutes apart by the same coordinator (intraoperator assessment) or by a second coordinator (interoperator assessment) in a subset of participants.
STATISTICAL ANALYSIS
Demographics, anthropometrics, liver tests, serum chemistries, histologic characteristics, and FibroScan metrics were compared between M1 and XL1 probe types using chi-squared tests for categorical variables and t tests for continuous variables. Both means with standard deviations and medians with interquartile range were presented for FibroScan data due to possible non-normality of the distribution. Correlation between the first and second readings used Spearman's correlation coefficient and Fisher's z-transformation.
The unreliability of LSM values was defined as the interquartile range (IQR)/median >30%. Significant disagreement between the first and second readings was defined as the absolute value of the difference in >95% limits of agreement between the two readings; i.e., using linear regression, the difference between the two readings of LSM and CAP was not related to the mean of the two readings. This was further visualized using Bland-Altman plots. The Bland-Altman plot analysis is a simple way to evaluate a bias between the mean differences and to estimate an agreement interval within which 95% of the differences of the second method, compared to the first one, fall. It simply quantifies the bias and a range of agreement within which 95% of the differences between one measurement and the other are included. It is also possible to say that the bias is significant when the line of equality is not within the confidence interval of the mean difference. For analyses of LSM and CAP, the mean of the two readings or the first reading if the second reading was missing was used; observations with missing data for the second reading (n 5 28 for LSM, n 5 24 for CAP) were excluded from selected analyses of interobserver and intraobserver differences of LSM and CAP. The CAP data for 183 patients were missing due to a computer software problem using the XL1 probe at the start of FibroScan assessments.
Multiple logistic regression with Akaike's information criterion was used to assess associations for the binary outcomes of unreliability and significant disagreement from a candidate set including age, gender, ethnicity, race, BMI, waist circumference, LSM (or CAP), international normalized ratio, alanine aminotransferase, aspartate aminotransferase, serum bilirubin, serum alkaline phosphatase, blood platelet count, steatosis score, fibrosis stage, NASH diagnosis, time from biopsy, probe type, and same or different operator. Robust multiple linear regression was used to test for differences by probe type in LSM adjusted for fibrosis stage and BMI and CAP adjusted for steatosis score and BMI. (39) LSM was modeled both untransformed and log-transformed due to non-normality of the distribution. All analyses were conducted using SAS (version 9.3 of the SAS System for Windows; SAS Institute Inc., Cary, NC) and Stata (release 14; StataCorp LP, College Station, TX).
Results
STUDY POPULATION
Individuals who underwent evaluation with VCTE as part of the NAFLD Database 2 Study between April 2014 and May 2016 (n 5 992) were included in this analysis. Of them, 964 had two VCTE examinations back to back, with a second VCTE procedure by the same operator in 838 patients and by a different operator in 123 patients (3 unknown operator). The total numbers of LSM and CAP available for analysis were 1,956 and 1,594, respectively.
The selected clinical, laboratory, and histological features of our study cohort are described in Table 1 . Overall, the mean age was 51 years, with 65% women and the cohort being predominantly Caucasian (84%, with 10% Hispanic ethnicity). The mean BMI was 33.6 6 6.5 kg/m 2 , with 31% belonging to the normal/ overweight and obese categories each and the remaining 36% belonging to the extreme obese category ( Table 1 ). The study cohort consisted predominantly of NASH patients, with 53% showing definite NASH and 19% exhibiting borderline NASH. The mean duration between liver biopsy and VCTE was 2.4 years. Histograms of LSM (Fig. 1A) and CAP (Fig.  1B) showed a right-skewed distribution for LSM and a normal distribution for CAP.
VCTE FAILURE RATE
The failure rate for VCTE for obtaining LSM and CAP was 3.2% (55/1,696) based on the total number of scans performed in the current study. The failure rate based on the total number of patients included in this study was slightly higher at 5.5% (55/992). The three most frequent reasons for failure were inability to obtain a scan due to excess skin to liver capsule distance (n 5 19 patients), machine/technician error (n 5 13 patient), and patient refusal (n 5 11). Other reasons included invalid readings (n 5 6 patients), intolerable pain (n 5 4 patients), undetectable liver (n 5 1), and unknown (n 5 1).
PERFORMANCE CHARACTERISTICS
Both median LSM and median CAP values were significantly higher in the higher BMI categories ( Table 2) . Use of the XL1 probe was significantly greater in higher BMI categories, i.e., 27% in normal/ overweight, 61% in obese, and 87% in extreme obese patients (P < 0.001). The mean difference between the first and second readings of LSM was 0.0 6 5.5 kPa and did not significantly differ among different BMI categories ( Table 2 ). The mean difference between the first and second CAP readings was 2 6 36 dB/m, and it was also not significantly different among various BMI categories ( Table 2 ). The BlandAltman plot to describe the agreement between the two LSM readings showed that 95% of the difference between the first and second readings occurred within 62.9 kPa with no bias over the range of values (2-75 kPa) (Fig. 1C) . Similarly, the Bland-Altman plot to describe the agreement between the two CAP readings showed that 95% of the difference between the first and second readings occurred within 651 dB/m with no bias over the range of values (100-400 dB/m) (Fig. 1D) .
FACTORS ASSOCIATED WITH UNRELIABLE LSM
Unreliable results due to significant variability, i.e., median LSM values with IQR/median >30%, were found in 3.9% (39/992) of patients. The unreliability rate using exams as the denominator was 4.9% (95/ 1,956). The relationship between operator experience in quartiles and the proportion of unreliable scans was first examined (Table 3 ). The proportion of unreliable scans in the fourth quartile was 1.6%, which was significantly lower than first three quarters combined (4.7%, P 5 0.02 by Fisher's exact test). The logistic regression model with all variables from Table 1 using Akaike's information criterion showed that BMI (Table 4 ). There was a 25% decrease in the odds of unreliability per increasing quartile of prior exams adjusted for other confounders (OR, 0.75; 95% CI, 0.52-1.08; P 5 0.12) ( Table 4) .
FACTORS ASSOCIATED WITH SIGNIFICANT DISAGREEMENT BETWEEN THE FIRST AND SECOND VCTE READINGS
Values of LSM and CAP between the first and second exams were compared, and significant disagreement was defined as the absolute value of the difference in >95% limits of agreement between the two readings. Using linear regression, the difference between the two readings of LSM and CAP was not related to the mean of the two readings: change in LSM difference/1 unit increase in LSM mean 5 0.002 kPa (SE 5 0.016); change in CAP difference/1 unit increase in CAP mean 5 -0.001 dB/m (SE 5 0.024). This can also be seen in the Bland-Altman plots in Fig. 1C,D . The rate of significant disagreement for LSM was 18% (169 out of 964 paired LSM measurements), while the rate of significant disagreement for CAP was 11% (85 out of 785 paired CAP measurements). The factors associated with significant disagreement between first and second measurements of LSM and CAP are shown in Table 5 . While the significant disagreement between two LSM values increased with increasing LSM score (per kPa) (OR, 1.06; 95% CI, 1.04-1.09; P < 0.001), higher fibrosis stage (OR, 1.22; 95% CI, 1.02-1.46; P 5 0.03), and aspartate aminotransferase (per 10 U/L) (OR, 1.07; 95% CI, 1.01-1.13; P 5 0.03), factors such as male gender (OR, 0.52; 95% CI, 0.32-0.86; P 5 0.01), white race (OR, 0.50; 95% CI, 0.26-0.96; P 5 0.04), and platelet count (per 10K cells/uL) (OR, 0.96; 95% CI, 0.93-1.00; P 5 0.04) were associated with lower significant disagreement. Factors associated with less disagreement between first and second CAP scores were higher CAP (per 10 dB/m) values (OR, 0.91; 95% CI, 0.86-0.96; P 5 0.001) and steatosis grade (OR, 0.67; 95% CI, 0.49-0.92; P 5 0.01). Waist circumference (per cm) was associated with higher disagreement in both CAP (OR, 1.03; 95% CI, 1.01-1.05; P 5 0.006) and LSM (OR, 1.02; 95% CI, 1.00-1.04; P 5 0.09) ( Table 5) .
The correlation between the first and second measurements obtained by the same coordinator (intraobserver) and by a different coordinator (interobserver) was assessed in 838 and 123 participants, respectively. The correlation between the first and second readings was high for both interoperator (r 5 0.84) and intraoperator (r 5 0.90) LSM values. This correlation was significantly higher when the M1 probe was used compared to the XL1 probe (interoperator r 5 0.90 versus 0.77, P 5 0.02; intraoperator r 5 0.94 versus 0.87, P < 0.001). The correlation between the first and second CAP readings was high for both interoperator (r 5 0.70) and intraoperator (r 5 0.82) values. The interoperator correlation did not differ by M1 versus XL1 probe type (r 5 0.64 versus 0.68, P 5 0.71), but the intraoperator correlation was significantly higher using the M1 versus the XL1 probe (r 5 0.85 versus 0.75, P <0.001). 
PROBE SIZE AND PERFORMANCE CHARACTERISTICS
The mean and median LSM values with the XL1 probe were significantly higher than values with the M1 probe (mean 6 SD 12.5 6 13.1 versus 9.7 6 8.8 kPa, P < 0.001; median [IQR] 5 7.9 [5.7-13.6] versus 6.8 [4.9-10.8] kPa, P < 0.0001). However, when adjusted for BMI and fibrosis stage, mean LSM using the M1 probe was significantly higher by 0.8 kPa (95% CI, 0.3-1.4; P 5 0.003) compared to the XL1 probe, and the ratio of LSM using M1/XL1 was significantly higher by 6% (95% CI, 3%-9%; P < 0.001) (backtransforming log LSM) ( Table 6 ). The mean CAP score in the XL1 probe group was significantly higher than that in the M1 probe group (326 6 47 versus 288 6 52 dB/m, P < 0.001). When adjusted for BMI and severity of hepatic steatosis by histology, CAP scores obtained using the XL1 probe were higher by 16 dB/m (95% CI, 8-24; P < 0.001) ( Table 6 ).
Discussion
The VCTE examination offers an opportunity to noninvasively assess the extent of liver fibrosis and hepatic steatosis in patients with NAFLD in an outpatient clinic setting. Moreover, the change in LSM and CAP values over time may provide an opportunity to monitor disease progression without a liver biopsy. Soon after its approval in 2013, there was interest in incorporating VCTE into ambulatory gastroenterology and hepatology practices throughout North America. However, the performance of VCTE with the FibroScan 502 Touch, which offers two probes and an automated probe selection by the device, is not well understood.
The main findings from this study are that (1) the failure rate for obtaining valid LSM and CAP using currently available VCTE device and software technology is quite minimal, (2) unreliable LSMs are rare but associated with obesity and operator inexperience, and (3) reproducibility of LSM and CAP measurement is high whether the test is repeated by the same or by a different operator.
In a recent study conducted in the United States by Tapper et al., VCTE was performed in 164 patients with NAFLD using an M1 probe, with a reported 73% success rate for obtaining reliable LSM, which was defined as 10 valid measurements and IQR 30% of the median. (20) If we apply the same definition as Tapper et al., (20) the success rate for VCTE in our experience was high at 94%. We believe the improved performance of the VCTE in our study is due to the availability of the XL1 probe, which was used in 60% of the participants. In the study by Tapper et al., extreme obesity was strongly associated with uninterpretable VCTE results when obtained with an M1 probe (OR, 8.76; 95% CI 3.82-21.0). In our study, nearly 90% of the extremely obese participants had their VCTE performed with an XL1 probe, thus overcoming the limitation of the M1 probe in obtaining a valid reading in those with extreme obesity. Finally, Hispanic ethnicity was associated with unreliable LSM in the current cohort. We suspect that this association may be related to greater prevalence of abdominal adiposity, shorter height, and possibly smaller intercostal space. The divergent relationship between the LSM and CAP values with the size of the probe is interesting. Although caution should be exercised in interpreting these findings because these values were not obtained using both probes in the same patient, the current study revealed that LSM values with the XL1 probe are lower by 0.8 kPa, while CAP values are increased by approximately 16 dB/m. Although the lower LSM values by the XL1 probe, compared to the M1 probe in the same individual, have been described before, (40) a higher CAP value with the XL1 probe for a similar degree for steatosis is a novel finding. These results are important when interpreting the changes in the values of LSM and CAP during the course of a longitudinal study when the size of the probe may inadvertently change. Therefore, consideration should be given for 61 kPa and 616 kPa when establishing a threshold cutoff for the stage of fibrosis and degree of steatosis, respectively.
An important shortcoming of this study is that it did not examine the relationship between LSM and CAP and liver histology because the mean duration between liver biopsy and VCTE was 2.6 years. We believe that it is best to investigate the relationship between VCTE and liver histology obtained at a much closer interval. In a study from the NASH CRN, the relationship between serum keratin 18 fragments and liver histology was much stronger when they were measured in close proximity to the liver biopsy. (41) In summary, VCTE for estimation of LSM and CAP can be successfully deployed in a multicenter setting with a very low failure rate (<2.5%) and a high reliability rate (>95%). Although the reasons for failure and unreliable scans appear to be related to factors associated with the patient, VCTE technology, or the operator, the current study suggests that, with sufficient operator experience, it is possible to minimize failure and unreliability rates. Our study demonstrates high performance characteristics for currently available VCTE, supporting its use in clinical practice and in a multicenter research setting.
